- Home
- Publications
- Publication Search
- Publication Details
Title
Tazemetostat: First Approval
Authors
Keywords
-
Journal
DRUGS
Volume 80, Issue 5, Pages 513-521
Publisher
Springer Science and Business Media LLC
Online
2020-03-12
DOI
10.1007/s40265-020-01288-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
- (2020) Franck Morschhauser et al. BLOOD
- Combined tazemetostat and MAPKi enhances differentiation of papillary thyroid cancer cells harbouring BRAF V600E by synergistically decreasing global trimethylation of H3K27
- (2020) Hao Fu et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB IN COMBINATION WITH TAZEMETOSTAT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B STUDY
- (2019) M.L. Palomba et al. HEMATOLOGICAL ONCOLOGY
- Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
- (2018) Antoine Italiano et al. LANCET ONCOLOGY
- Enhancer of zeste homolog 2 (EZH2) inhibitors
- (2018) Nitya Gulati et al. LEUKEMIA & LYMPHOMA
- Abstract 808: Opportunity for therapeutic expansion in mantle cell lymphoma: Tazemetostat combination synergy status in preclinical MCL models
- (2018) Tami L. Hood et al. CANCER RESEARCH
- Phase 2, multicenter study of the EZH2 inhibitor tazemetostat as monotherapy in adults with relapsed or refractory (R/R) malignant mesothelioma (MM) with BAP1 inactivation.
- (2018) Marjorie Glass Zauderer et al. JOURNAL OF CLINICAL ONCOLOGY
- Emerging EZH2 Inhibitors and Their Application in Lymphoma
- (2018) Jennifer K. Lue et al. Current Hematologic Malignancy Reports
- 1612PDA phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (rhabdoid tumor cohort) (NCT02601950)
- (2018) R L Jones et al. ANNALS OF ONCOLOGY
- 1611PDA phase II, multicenter study of the EZH2 inhibitor tazemetostat in adults (INI1-negative tumors cohort) (NCT02601950)
- (2018) S Stacchiotti et al. ANNALS OF ONCOLOGY
- Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models
- (2017) Elayne Chan-Penebre et al. MOLECULAR CANCER THERAPEUTICS
- Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma
- (2014) S. K. Knutson et al. MOLECULAR CANCER THERAPEUTICS
- Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2
- (2013) S. K. Knutson et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- INI1-Deficient Tumors
- (2011) Travis J. Hollmann et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started